Wesley Baas1, Svetlana Gershburg2, Danuta Dynda1, Kristin Delfino2, Kathy Robinson3, Daotai Nie4, Jennifer Holmes Yearley5, Shaheen Alanee6. 1. Division of Urology, Southern Illinois University School of Medicine, Springfield, IL. 2. Center for Clinical Research, Southern Illinois University School of Medicine, Springfield, IL. 3. Cancer Institute, Southern Illinois University School of Medicine, Springfield, IL. 4. Department of Med Micro, Immunology, and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL. 5. Merck Research Laboratories, Palo Alto, CA. 6. Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI. Electronic address: salanee1@hfhs.org.
Abstract
BACKGROUND: Programmed cell death-1 (PD-1), a T-cell inhibitory receptor, and its ligand, PD-L1, have been reported to be expressed in many tumor types, and this expression has led to the development of many drugs targeting the PD-1 pathway. The objective of this study was to determine the expression of PD-1 and PD-L1 in high-grade prostate cancer tissues, and correlate the expression with disease and patient characteristics. MATERIALS AND METHODS: Immunohistochemistry for PD-1 (CD279), PD-L1 (B7-H1), and CD3 was performed and scored from 0 to 5 on prostatectomy/biopsy tissue samples taken from 25 men with high-grade prostate cancer. Charts were then retrospectively reviewed for numerous patient and disease characteristics. Statistical analyses were done to investigate the association of these patient and disease characteristics with PD-1, PD-L1, and CD3 expression. RESULTS: A score of 3 to 5 on the semiquantitative 0 to 5 score was deemed "high" expression whereas a score of 0 to 2 was deemed "low" expression. Of the 25 samples, 2 (8%) scored high for PD-1 expression, 2 (8%) scored high for PD-L1 expression, and 18 (72%) scored high for CD3 expression. There was no statistically significant difference between high and low expression groups of PD-1, PD-L1, or CD3 for any of the variables we collected. CONCLUSION: An overall low expression of PD-1 and PD-L1, and a concurrent high expression of CD3+ T cells was found in high-risk prostate cancer tissue. No significant association was found between expression of PD-1, PD-L1, or CD3, and patient or disease characteristics. Because of this, one might be able to question the role of PD-L1 in local immune suppression in prostate cancer.
BACKGROUND: Programmed cell death-1 (PD-1), a T-cell inhibitory receptor, and its ligand, PD-L1, have been reported to be expressed in many tumor types, and this expression has led to the development of many drugs targeting the PD-1 pathway. The objective of this study was to determine the expression of PD-1 and PD-L1 in high-grade prostate cancer tissues, and correlate the expression with disease and patient characteristics. MATERIALS AND METHODS: Immunohistochemistry for PD-1 (CD279), PD-L1 (B7-H1), and CD3 was performed and scored from 0 to 5 on prostatectomy/biopsy tissue samples taken from 25 men with high-grade prostate cancer. Charts were then retrospectively reviewed for numerous patient and disease characteristics. Statistical analyses were done to investigate the association of these patient and disease characteristics with PD-1, PD-L1, and CD3 expression. RESULTS: A score of 3 to 5 on the semiquantitative 0 to 5 score was deemed "high" expression whereas a score of 0 to 2 was deemed "low" expression. Of the 25 samples, 2 (8%) scored high for PD-1 expression, 2 (8%) scored high for PD-L1 expression, and 18 (72%) scored high for CD3 expression. There was no statistically significant difference between high and low expression groups of PD-1, PD-L1, or CD3 for any of the variables we collected. CONCLUSION: An overall low expression of PD-1 and PD-L1, and a concurrent high expression of CD3+ T cells was found in high-risk prostate cancer tissue. No significant association was found between expression of PD-1, PD-L1, or CD3, and patient or disease characteristics. Because of this, one might be able to question the role of PD-L1 in local immune suppression in prostate cancer.
Authors: Michael C Haffner; Gunes Guner; Diana Taheri; George J Netto; Doreen N Palsgrove; Qizhi Zheng; Liana Benevides Guedes; Kunhwa Kim; Harrison Tsai; David M Esopi; Tamara L Lotan; Rajni Sharma; Alan K Meeker; Arul M Chinnaiyan; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Rohit Mehra; Emmanuel S Antonarakis; Charles G Drake; Angelo M De Marzo Journal: Am J Pathol Date: 2018-03-22 Impact factor: 4.307
Authors: Ulrich Sommer; Celina Ebersbach; Alicia-Marie K Beier; Gustavo B Baretton; Christian Thomas; Angelika Borkowetz; Holger H H Erb Journal: Front Mol Biosci Date: 2022-06-28
Authors: Vicenç Ruiz de Porras; Juan Carlos Pardo; Lucia Notario; Olatz Etxaniz; Albert Font Journal: Int J Mol Sci Date: 2021-04-29 Impact factor: 5.923